Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 177

1.

Modelling of radon hazards in underground mine workings.

Skubacz K, Wysocka M, Michalik B, Dziurzyński W, Krach A, Krawczyk J, Pałka T.

Sci Total Environ. 2019 Aug 8;695:133853. doi: 10.1016/j.scitotenv.2019.133853. [Epub ahead of print]

PMID:
31422316
2.

Structure-based design and in vivo anti-arthritic activity evaluation of a potent dipeptidyl cyclopropyl nitrile inhibitor of cathepsin C.

Korkmaz B, Lesner A, Wysocka M, Gieldon A, Håkansson M, Gauthier F, Logan DT, Jenne DE, Lauritzen C, Pedersen J.

Biochem Pharmacol. 2019 Jun;164:349-367. doi: 10.1016/j.bcp.2019.04.006. Epub 2019 Apr 9.

PMID:
30978322
3.

Development of Chemical Tools to Monitor Human Kallikrein 13 (KLK13) Activity.

Gruba N, Bielecka E, Wysocka M, Wojtysiak A, Brzezińska-Bodal M, Sychowska K, Kalińska M, Magoch M, Pęcak A, Falkowski K, Wiśniewska M, Sąsiadek L, Płaza K, Kroll E, Pejkovska A, Rehders M, Brix K, Dubin G, Kantyka T, Potempa J, Lesner A.

Int J Mol Sci. 2019 Mar 28;20(7). pii: E1557. doi: 10.3390/ijms20071557.

4.

Host and pathogen factors in Klebsiella pneumoniae upper urinary tract infections in renal transplant patients.

Gołębiewska JE, Krawczyk B, Wysocka M, Ewiak A, Komarnicka J, Bronk M, Rutkowski B, Dębska-Ślizień A.

J Med Microbiol. 2019 Mar;68(3):382-394. doi: 10.1099/jmm.0.000942. Epub 2019 Feb 12.

PMID:
30747620
5.

Conjugate of Enkephalin and Temporin Peptides as a Novel Therapeutic Agent for Sepsis.

Golda A, Kosikowska-Adamus P, Babyak O, Lech M, Wysocka M, Lesner A, Potempa J, Koziel J.

Bioconjug Chem. 2018 Dec 19;29(12):4127-4139. doi: 10.1021/acs.bioconjchem.8b00763. Epub 2018 Dec 10.

PMID:
30525485
6.

The correlation between the concentration of hepcidin in serum and the occurrence of insulin resistance and hyperandrogenemia in women with polycystic ovary syndrome.

Pluta D, Franik G, Blukacz Ł, Kowalczyk K, Witkowska A, Wysocka M, Madej P.

Eur Rev Med Pharmacol Sci. 2018 Nov;22(21):7379-7384. doi: 10.26355/eurrev_201811_16276.

7.

One Step Beyond: Design of Substrates Spanning Primed Positions of Zika Virus NS2B-NS3 Protease.

Gruba N, Martinez JIR, Grzywa R, Wysocka M, Skoreński M, Dabrowska A, Łęcka M, Suder P, Sieńczyk M, Pyrc K, Lesner A.

ACS Med Chem Lett. 2018 Aug 28;9(10):1025-1029. doi: 10.1021/acsmedchemlett.8b00316. eCollection 2018 Oct 11.

8.

Safety profile of a single pegylated asparaginase (PEG-ASP) dose in remission induction for acute lymphoblastic leukemia (ALL).

Helbig G, Armatys A, Boral K, Kopinska AJ, Wozniczka K, Dworaczek M, Chromik K, Koclega A, Panz-Klapuch M, Wysocka M, Janikowska A.

Neoplasma. 2018 Nov 15;65(6):993-997. doi: 10.4149/neo_2018_180214N121. Epub 2018 Jun 17.

PMID:
29940768
9.

The Role of Apelin in Cardiovascular Diseases, Obesity and Cancer.

Wysocka MB, Pietraszek-Gremplewicz K, Nowak D.

Front Physiol. 2018 May 23;9:557. doi: 10.3389/fphys.2018.00557. eCollection 2018. Review.

10.

Design, Synthesis, and Enzymatic Evaluation of Novel ZnO Quantum Dot-Based Assay for Detection of Proteinase 3 Activity.

Popow-Stellmaszyk J, Bajorowicz B, Malankowska A, Wysocka M, Klimczuk T, Zaleska-Medynska A, Lesner A.

Bioconjug Chem. 2018 May 16;29(5):1576-1583. doi: 10.1021/acs.bioconjchem.8b00100. Epub 2018 Apr 20.

PMID:
29641897
11.

Synthesis and antimicrobial activity of amino acid and peptide derivatives of mycophenolic acid.

Siebert A, Wysocka M, Krawczyk B, Cholewiński G, Rachoń J.

Eur J Med Chem. 2018 Jan 1;143:646-655. doi: 10.1016/j.ejmech.2017.11.094. Epub 2017 Dec 1.

PMID:
29216563
12.

Fusion of DNA-binding domain of Pyrococcus furiosus ligase with TaqStoffel DNA polymerase as a useful tool in PCR with difficult targets.

Śpibida M, Krawczyk B, Zalewska-Piątek B, Piątek R, Wysocka M, Olszewski M.

Appl Microbiol Biotechnol. 2018 Jan;102(2):713-721. doi: 10.1007/s00253-017-8560-6. Epub 2017 Nov 4.

13.

MEASUREMENTS OF AIRBORNE CONCENTRATIONS OF RADON AND THORON DECAY PRODUCTS.

Chalupnik S, Skubacz K, Urban P, Wysocka M.

Radiat Prot Dosimetry. 2017 Nov 1;177(1-2):45-48. doi: 10.1093/rpd/ncx164.

PMID:
29036704
14.

RADON CHAMBER IN THE CENTRAL MINING INSTITUTE-THE CALIBRATION FACILITY FOR RADON AND RADON PROGENY MONITORS.

Skubacz K, Chalupnik S, Urban P, Wysocka M.

Radiat Prot Dosimetry. 2017 Nov 1;177(1-2):164-167. doi: 10.1093/rpd/ncx177.

PMID:
29036377
15.

Quinacrine Suppresses Tumor Necrosis Factor-α and IFN-α in Dermatomyositis and Cutaneous Lupus Erythematosus.

Alves P, Bashir MM, Wysocka M, Zeidi M, Feng R, Werth VP.

J Investig Dermatol Symp Proc. 2017 Oct;18(2):S57-S63. doi: 10.1016/j.jisp.2016.11.001.

16.

Selection of Effective HTRA3 Activators Using Combinatorial Chemistry.

Wysocka M, Sychowska K, Gruba N, Winiarski Ł, Skoreński M, Psurski M, Makowska J, Giełdoń A, Wenta T, Jarząb M, Glaza P, Zdancewicz J, Sieńczyk M, Lipińska B, Lesner A.

ACS Comb Sci. 2017 Sep 11;19(9):565-573. doi: 10.1021/acscombsci.7b00051. Epub 2017 Aug 24.

PMID:
28741928
17.

Long term changes in the concentration of radium in discharge waters of coal mines and Upper Silesian rivers.

Chałupnik S, Wysocka M, Janson E, Chmielewska I, Wiesner M.

J Environ Radioact. 2017 May;171:117-123. doi: 10.1016/j.jenvrad.2017.02.007. Epub 2017 Feb 22.

PMID:
28235699
18.

Gain of CD26 expression on the malignant T-cells in relapsed erythrodermic leukemic mycosis fungoides.

Cedeno-Laurent F, Wysocka M, Obstfeld AE, Novoa RA, Vittorio CC, Kim EJ, Weng WK, Rook AH.

J Cutan Pathol. 2017 May;44(5):462-466. doi: 10.1111/cup.12899. Epub 2017 Feb 10.

PMID:
28083948
19.

Substrate profiling of Zika virus NS2B-NS3 protease.

Gruba N, Rodriguez Martinez JI, Grzywa R, Wysocka M, Skoreński M, Burmistrz M, Łęcka M, Lesner A, Sieńczyk M, Pyrć K.

FEBS Lett. 2016 Oct;590(20):3459-3468. doi: 10.1002/1873-3468.12443. Epub 2016 Oct 18.

20.

TIGIT and Helios Are Highly Expressed on CD4+ T Cells in Sézary Syndrome Patients.

Jariwala N, Benoit B, Kossenkov AV, Oetjen LK, Whelan TM, Cornejo CM, Takeshita J, Kim BS, Showe LC, Wysocka M, Rook AH.

J Invest Dermatol. 2017 Jan;137(1):257-260. doi: 10.1016/j.jid.2016.08.016. Epub 2016 Sep 1. No abstract available.

21.

CD164 identifies CD4+ T cells highly expressing genes associated with malignancy in Sézary syndrome: the Sézary signature genes, FCRL3, Tox, and miR-214.

Benoit BM, Jariwala N, O'Connor G, Oetjen LK, Whelan TM, Werth A, Troxel AB, Sicard H, Zhu L, Miller C, Takeshita J, McVicar DW, Kim BS, Rook AH, Wysocka M.

Arch Dermatol Res. 2017 Jan;309(1):11-19. doi: 10.1007/s00403-016-1698-8. Epub 2016 Oct 20.

22.

Inhibitors and Antibody Fragments as Potential Anti-Inflammatory Therapeutics Targeting Neutrophil Proteinase 3 in Human Disease.

Korkmaz B, Lesner A, Guarino C, Wysocka M, Kellenberger C, Watier H, Specks U, Gauthier F, Jenne DE.

Pharmacol Rev. 2016 Jul;68(3):603-30. doi: 10.1124/pr.115.012104. Review.

PMID:
27329045
23.

Bladder cancer detection using a peptide substrate of the 20S proteasome.

Gruba N, Wysocka M, Brzezińska M, Dębowski D, Sieńczyk M, Gorodkiewicz E, Guszcz T, Czaplewski C, Rolka K, Lesner A.

FEBS J. 2016 Aug;283(15):2929-48. doi: 10.1111/febs.13786. Epub 2016 Jul 14.

24.

PEGylated substrates of NSP4 protease: A tool to study protease specificity.

Wysocka M, Gruba N, Grzywa R, Giełdoń A, Bąchor R, Brzozowski K, Sieńczyk M, Dieter J, Szewczuk Z, Rolka K, Lesner A.

Sci Rep. 2016 Mar 9;6:22856. doi: 10.1038/srep22856.

25.

Intra- and intersubunit changes accompanying thermal activation of the HtrA2(Omi) protease homotrimer.

Jarzab M, Wenta T, Zurawa-Janicka D, Polit A, Gieldon AJ, Wysocka M, Glaza P, Skorko-Glonek J, Ciarkowski J, Lesner A, Lipinska B.

Biochim Biophys Acta. 2016 Mar;1864(3):283-296. doi: 10.1016/j.bbapap.2015.12.002. Epub 2015 Dec 15.

PMID:
26702898
26.

Novel internally quenched substrate of the trypsin-like subunit of 20S eukaryotic proteasome.

Gruba N, Wysocka M, Brzezińska M, Debowski D, Rolka K, Martin NI, Lesner A.

Anal Biochem. 2016 Sep 1;508:38-45. doi: 10.1016/j.ab.2015.08.019. Epub 2015 Aug 24.

PMID:
26314791
27.

Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma.

Rook AH, Gelfand JM, Wysocka M, Troxel AB, Benoit B, Surber C, Elenitsas R, Buchanan MA, Leahy DS, Watanabe R, Kirsch IR, Kim EJ, Clark RA.

Blood. 2015 Sep 17;126(12):1452-61. doi: 10.1182/blood-2015-02-630335. Epub 2015 Jul 30. Erratum in: Blood. 2015 Dec 17;126(25):2765. Gelfand, Joel C [corrected to Gelfand, Joel M].

28.

Improved pruritus correlates with lower levels of IL-31 in CTCL patients under different therapeutic modalities.

Cedeno-Laurent F, Singer EM, Wysocka M, Benoit BM, Vittorio CC, Kim EJ, Yosipovitch G, Rook AH.

Clin Immunol. 2015 May;158(1):1-7. doi: 10.1016/j.clim.2015.02.014. Epub 2015 Mar 8.

29.

Design and synthesis of new substrates of HtrA2 protease.

Wysocka M, Wojtysiak A, Okońska M, Gruba N, Jarząb M, Wenta T, Lipińska B, Grzywa R, Sieńczyk M, Rolka K, Lesner A.

Anal Biochem. 2015 Apr 15;475:44-52. doi: 10.1016/j.ab.2015.01.013. Epub 2015 Jan 29.

PMID:
25640585
30.

New selective peptidyl di(chlorophenyl) phosphonate esters for visualizing and blocking neutrophil proteinase 3 in human diseases.

Guarino C, Legowska M, Epinette C, Kellenberger C, Dallet-Choisy S, Sieńczyk M, Gabant G, Cadene M, Zoidakis J, Vlahou A, Wysocka M, Marchand-Adam S, Jenne DE, Lesner A, Gauthier F, Korkmaz B.

J Biol Chem. 2014 Nov 14;289(46):31777-91. doi: 10.1074/jbc.M114.591339. Epub 2014 Oct 6.

31.

Synthesis of novel phosphonic-type activity-based probes for neutrophil serine proteases and their application in spleen lysates of different organisms.

Grzywa R, Burchacka E, Łęcka M, Winiarski Ł, Walczak M, Łupicka-Słowik A, Wysocka M, Burster T, Bobrek K, Csencsits-Smith K, Lesner A, Sieńczyk M.

Chembiochem. 2014 Nov 24;15(17):2605-12. doi: 10.1002/cbic.201402360. Epub 2014 Sep 18.

PMID:
25236966
32.

Eating habits of patients with cleft lip and palate terated with fixed appliances.

Wysocka M, Cudziło D, Kawala B, Kopczyński P.

Dev Period Med. 2014;18(1):93-101.

33.

Ultrasensitive internally quenched substrates of human cathepsin L.

Lęgowska M, Wysocka M, Burster T, Pikuła M, Rolka K, Lesner A.

Anal Biochem. 2014 Dec 1;466:30-7. doi: 10.1016/j.ab.2014.08.010. Epub 2014 Aug 23.

PMID:
25151941
34.

Substrate profiling of Finegoldia magna SufA protease, inhibitor screening and application to prevent human fibrinogen degradation and bacteria growth in vitro.

Burchacka E, Sieńczyk M, Frick IM, Wysocka M, Lesner A, Oleksyszyn J.

Biochimie. 2014 Aug;103:137-43. doi: 10.1016/j.biochi.2014.05.006. Epub 2014 May 22.

PMID:
24859537
35.

Fluorescent analogs of trypsin inhibitor SFTI-1 isolated from sunflower seeds--synthesis and applications.

Lesner A, Karna N, Psurski M, Lęgowska A, Wysocka M, Guzow K, Sieradzan A, Sieńczyk M, Trzonkowski P, Pikuła M, Zieliński M, Kosikowska P, Łukajtis R, Łęgowska M, Dębowski D, Wiczk W, Rolka K.

Biopolymers. 2014 Jan;102(1):124-35. doi: 10.1002/bip.22442.

PMID:
24272319
36.

Prophylaxis in children with haemophilia - the Polish experience.

Klukowska A, Urasinski T, Janik-Moszant A, Bobrowska H, Balwierz W, Woznica-Karczmarz I, Dobaczewski G, Wlazlowski M, Koltan A, Badowska W, Dakowicz L, Karolczyk G, Kostrzewska M, Korczowski B, Wasinski D, Pietrys D, Laguna P, Wysocka M.

Haemophilia. 2014 Jan;20(1):e108-10. doi: 10.1111/hae.12327. Epub 2013 Nov 20. No abstract available.

PMID:
24251651
37.

Substrate specificity of human matriptase-2.

Wysocka M, Gruba N, Miecznikowska A, Popow-Stellmaszyk J, Gütschow M, Stirnberg M, Furtmann N, Bajorath J, Lesner A, Rolka K.

Biochimie. 2014 Feb;97:121-7. doi: 10.1016/j.biochi.2013.10.001. Epub 2013 Oct 22.

PMID:
24161741
38.

Biochemical and structural characterization of SplD protease from Staphylococcus aureus.

Zdzalik M, Kalinska M, Wysocka M, Stec-Niemczyk J, Cichon P, Stach N, Gruba N, Stennicke HR, Jabaiah A, Markiewicz M, Kedracka-Krok S, Wladyka B, Daugherty PS, Lesner A, Rolka K, Dubin A, Potempa J, Dubin G.

PLoS One. 2013 Oct 9;8(10):e76812. doi: 10.1371/journal.pone.0076812. eCollection 2013.

39.

A new proteinase 3 substrate with improved selectivity over human neutrophil elastase.

Popow-Stellmaszyk J, Wysocka M, Lesner A, Korkmaz B, Rolka K.

Anal Biochem. 2013 Nov 1;442(1):75-82. doi: 10.1016/j.ab.2013.07.028. Epub 2013 Jul 30.

PMID:
23911525
40.

Application of zeolites for radium removal from mine water.

Chałupnik S, Franus W, Wysocka M, Gzyl G.

Environ Sci Pollut Res Int. 2013 Nov;20(11):7900-6. doi: 10.1007/s11356-013-1877-5. Epub 2013 Jul 24.

41.

CD164 and FCRL3 are highly expressed on CD4+CD26- T cells in Sézary syndrome patients.

Wysocka M, Kossenkov AV, Benoit BM, Troxel AB, Singer E, Schaffer A, Kim B, Dentchev T, Nagata S, Ise T, Showe LC, Rook AH.

J Invest Dermatol. 2014 Jan;134(1):229-236. doi: 10.1038/jid.2013.279. Epub 2013 Jun 21.

42.

IL-31 is produced by the malignant T-cell population in cutaneous T-Cell lymphoma and correlates with CTCL pruritus.

Singer EM, Shin DB, Nattkemper LA, Benoit BM, Klein RS, Didigu CA, Loren AW, Dentchev T, Wysocka M, Yosipovitch G, Rook AH.

J Invest Dermatol. 2013 Dec;133(12):2783-2785. doi: 10.1038/jid.2013.227. Epub 2013 May 22. No abstract available.

43.

Hybrid analogues of SFTI-1 modified in P₁ position by β- and γ-amino acids and N-substituted β-alanines.

Debowski D, Łukajtis R, Filipowicz M, Strzelecka P, Wysocka M, Łęgowska A, Lesner A, Rolka K.

Biopolymers. 2013 Apr;100(2):154-9. doi: 10.1002/bip.22184.

PMID:
23616099
44.

Future of protease activity assays.

Wysocka M, Lesner A.

Curr Pharm Des. 2013;19(6):1062-7. Review.

PMID:
23016691
45.

Three wavelength substrate system of neutrophil serine proteinases.

Wysocka M, Lesner A, Gruba N, Korkmaz B, Gauthier F, Kitamatsu M, Łęgowska A, Rolka K.

Anal Chem. 2012 Aug 21;84(16):7241-8. doi: 10.1021/ac301684w. Epub 2012 Aug 8.

PMID:
22823539
46.

Pegylated fluorescent peptides as substrates of proteolytic enzymes.

Wysocka M, Lesner A, Popow J, Łegowska M, Rolka K.

Protein Pept Lett. 2012 Dec;19(12):1237-44.

PMID:
22670663
47.

Inhibitory and antimicrobial activities of OGTI and HV-BBI peptides, fragments and analogs derived from amphibian skin.

Dębowski D, Łukajtis R, Łęgowska A, Karna N, Pikuła M, Wysocka M, Maliszewska I, Sieńczyk M, Lesner A, Rolka K.

Peptides. 2012 Jun;35(2):276-84. doi: 10.1016/j.peptides.2012.04.001. Epub 2012 Apr 9.

PMID:
22516177
48.

The histone deacetylase inhibitor, romidepsin, suppresses cellular immune functions of cutaneous T-cell lymphoma patients.

Kelly-Sell MJ, Kim YH, Straus S, Benoit B, Harrison C, Sutherland K, Armstrong R, Weng WK, Showe LC, Wysocka M, Rook AH.

Am J Hematol. 2012 Apr;87(4):354-60. doi: 10.1002/ajh.23112. Epub 2012 Feb 24.

49.

Tumor necrosis factor α release in peripheral blood mononuclear cells of cutaneous lupus and dermatomyositis patients.

Nabatian AS, Bashir MM, Wysocka M, Sharma M, Werth VP.

Arthritis Res Ther. 2012 Jan 4;14(1):R1. doi: 10.1186/ar3549.

50.

Sunflower trypsin inhibitor 1 as a molecular scaffold for drug discovery.

Lesner A, Łęgowska A, Wysocka M, Rolka K.

Curr Pharm Des. 2011 Dec;17(38):4308-17. Review.

PMID:
22204429

Supplemental Content

Loading ...
Support Center